Onyx, Bayer launch Nexavar trial; NICE chair says pharma overcharges;

> Onyx Pharmaceuticals and Bayer are enrolling patients in a late-stage trial of their drug Nexavar as a post-surgery treatment for liver cancer; Nexavar is already approved for liver cancer, but the companies want to extend it into adjuvant treatment. Report

> The chairman of the U.K.'s National Institute for Health and Clinical Excellence, the medical watchdog, has accused pharmaceutical companies of overcharging for drugs to boost their share price. Report

> GlaxoSmithKline told more than 30,000 patients in Australia to see their doctors about whether they should continue taking the diabetes meds Avandia or Avandamet; the advice comes as the Aussie Therapeutic Goods Administration changed the guidelines for the drugs' use in light of last year's studies linking them to heart failure. Report

> In a bid to cut legal costs, Pfizer is creating a stir among lawyers after selecting just one law firm to handle almost all of its employment-related litigation. Report

> A German company is in advanced talks to set up a factory in Malta to produce dietary supplements to assist people suffering from immune system problems, group CEO Edmund Krix said Friday. Report

> The bidding war for Elan Drug Technologies, a division of the big Irish biotech, just lost a key player. The private equity player Cinven has dropped out of the auction, leaving Bain Capital and TPG. Report

> Johnson & Johnson is having a hard time making its case to the FDA for using Doribax as a therapy for hospital-acquired pneumonia. The agency says it wants to see more information on the drug before giving the drug its stamp of approval for that indication. Report

> PTC Therapeutics' PTC124 proved promising in an early stage cystic fibrosis trial in Israel. Report

> Don't look for an end to biotech buyouts anytime soon, says the AP. Quoting a string of experts in the field, the article concludes that there's still a lot of pharma money out there in pursuit of new therapies. Report

> Twin brothers Thomas and Andreas Struengmann made a fortune selling their generic drug business back in 2005. Now they plan to invest a good bit of their money in Germany's biotech industry. Report

And Finally... Growing up with a pet dog could make you snore later in life. Report

Suggested Articles

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.

After Merck and Bayer's vericiguat scored in a heart failure trial, you'd expect potential rivals to brace themselves. Not so for Novartis'…